Galectin Therapeutics (GALT) to Release Quarterly Earnings on Thursday

Galectin Therapeutics (NASDAQ:GALT) will likely be releasing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Galectin Therapeutics to post earnings of ($0.11) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 20, 2025 at 7:30 AM ET.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Price Performance

Shares of Galectin Therapeutics stock opened at $5.50 on Wednesday. The business has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $3.33. Galectin Therapeutics has a one year low of $0.73 and a one year high of $6.55. The firm has a market capitalization of $354.63 million, a price-to-earnings ratio of -8.59 and a beta of 0.86.

Insider Buying and Selling at Galectin Therapeutics

In related news, major shareholder Fund L.P. 10X sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $4.94, for a total value of $247,000.00. Following the sale, the insider directly owned 5,872,207 shares in the company, valued at approximately $29,008,702.58. The trade was a 0.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Joel Lewis sold 14,420 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $6.07, for a total transaction of $87,529.40. Following the transaction, the chief executive officer owned 832,592 shares of the company’s stock, valued at $5,053,833.44. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 121,065 shares of company stock valued at $685,325. Company insiders own 52.60% of the company’s stock.

Institutional Investors Weigh In On Galectin Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GALT. Bank of America Corp DE boosted its holdings in shares of Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock worth $49,000 after acquiring an additional 19,316 shares during the period. XTX Topco Ltd lifted its holdings in Galectin Therapeutics by 226.6% during the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock worth $90,000 after purchasing an additional 29,699 shares in the last quarter. Marshall Wace LLP purchased a new stake in Galectin Therapeutics during the 2nd quarter worth about $64,000. Vivaldi Capital Management LP boosted its stake in Galectin Therapeutics by 210.0% in the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock worth $364,000 after purchasing an additional 116,815 shares during the period. Finally, Jane Street Group LLC purchased a new position in Galectin Therapeutics during the 2nd quarter valued at about $1,580,000. Institutional investors own 11.68% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on GALT. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Galectin Therapeutics in a research report on Thursday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.